Comparative Clinical Trial Of The Progestins R-2323 And Levonorgestrel Administered By Subdermal Implants

dc.creatorAlvarez F.
dc.creatorRobertson D.N.
dc.creatorde Oca V.M.
dc.creatorSivin I.
dc.creatorBrache V.
dc.creatorFaundes A.
dc.date1978
dc.date2015-06-30T12:52:37Z
dc.date2015-11-26T14:34:12Z
dc.date2015-06-30T12:52:37Z
dc.date2015-11-26T14:34:12Z
dc.date.accessioned2018-03-28T21:37:35Z
dc.date.available2018-03-28T21:37:35Z
dc.identifier
dc.identifierContraception. , v. 18, n. 2, p. 151 - 162, 1978.
dc.identifier107824
dc.identifier10.1016/0010-7824(78)90090-2
dc.identifierhttp://www.scopus.com/inward/record.url?eid=2-s2.0-0017888411&partnerID=40&md5=1931fc77b2e084a65af3e8bb6bee35ea
dc.identifierhttp://www.repositorio.unicamp.br/handle/REPOSIP/97574
dc.identifierhttp://repositorio.unicamp.br/jspui/handle/REPOSIP/97574
dc.identifier2-s2.0-0017888411
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/1248043
dc.descriptionA random assignment comparative clinical trial of the progestins R-2323 and levonorgestrel delivered by the subdermal implant mode was carried out to assess the relative merits of the two regimens. Six 3-cm polydimethylsiloxane capsules containing the drug were implanted subdermally in the ventral aspect of the forearm of each subject. There were 48 subjects in the group with implants containing R-2323 and 52 subjects in the group with implants containing levonorgestrel. The original design had called for 100 subjects in each group, but enrollments were stopped when elevated serum transaminase levels were reported in Chilean women using the same R-2323 regimen. There were no pregnancies in 504 months of use of the R-2323 and there was one pregnancy in 512 months of use of the levonorgestrel regimen. One year continuation rates were 72.9 for R-2323 and 69.2 for levonorgestrel. Bleeding irregularities were an important reason for discontinuations of the levonorgestrel implants. Prolonged intervals of amenorrhea were common in subjects using R-2323 which was considered to be a beneficial side effect in the population where anemia and poor nutrition are not uncommon. Transaminase levels showed only marginal increases. Although pruritus and acne were more common in subjects using R-2323 than levonorgestrel, androgenic side effects were much less common than reported from Chile and Finland. © 1978.
dc.description18
dc.description2
dc.description151
dc.description162
dc.descriptionConstruction Design Institute,et al.,HPDI - CCCC Highway Consultants Co. Ltd.,JSZS - Jiangsu Zhoushe Eng. Consult. Group Co., Ltd.,OVM - Liuzhou OVM Machinery Co. Ltd.,Tianjin Urban Constr. Group (TJUCG) - Tianjin Urban
dc.descriptionTejuja, Use of subcutaneous silastic capsules for long-term steroid contraception (1970) Am J Obstet Gynecol, 107, pp. 954-957
dc.descriptionCroxatto, Diaz, Atria, Cheviokoff, Rosatti, Oddo, Contraceptive action of megestrol acetate implants in women (1970) Contraception, 4, pp. 155-167
dc.descriptionCoutinho, Mattos, Sant'Anna, Filho, Silva, Tatum, Long term contraception by subcutaneous silastic capsules containing megestrol acetate (1970) Contraception, 2, pp. 313-321
dc.descriptionCoutinho, Mattos, Sant'Anna, Filho, Silva, Tatum, Further studies on long term contraception by subcutaneous silastic capsules containing megestrol acetate (1972) Contraception, 5, pp. 389-393
dc.descriptionCoutinho, Silva, One year contraception with norgestrienone subdermal silastic implants (1974) Fertil Steril, 25, pp. 170-176
dc.descriptionBhatmagar, Srivastava, Lakkar, Chandra, Hingorani, Larimas, Long term contraception of steroid releasing implants II.A preliminary report on long term contraception by a single silastic implant containing norethindrone acetate (ENTA) in women (1975) Contraception, 11, pp. 505-522
dc.descriptionCoutinho, Da Silva, Carreira, Chavez, Filho, Contraceptive effectiveness of silastic implants containing the progestin R-2323 (1975) Contraception, 11, pp. 625-636
dc.descriptionTatum, Coutinho, Filho, Sant'Anna, Acceptability of long term contraceptive steroid administration in human by subcutaneous silastic capsules (1969) Am J Obstet Gynecol, 105, pp. 1139-1143
dc.descriptionCroxatto, Diaz, Vera, Etchart, Atria, Fertility control in women with progestogen released in microquantities from subcutaneous silastic capsules (1969) Am J Obstet Gynecol, 105, pp. 1135-1138
dc.descriptionMora, Faundes, Pastore, Clinical evaluation of an oral progestin contraceptive, R-2323, 5 mg. administered at weekly intervals (1974) Contraception, 10, pp. 145-158
dc.descriptionRobertson, D.N. and Atkinson, L.E. Personal communicationCroxatto, H.B. Personal communicationsRodriguez, Faundes-Latham, Atkinson, An approach to the analysis of menstrual patterns in the critical evaluation of contraceptives (1976) Studies in Family Planning, 7, pp. 42-51
dc.descriptionLuukkainen, T. Personal communicationDiaz, Pavez, Quinteras, Robertson, Croxatto, Clinical trial with subdermal implants of the progestin R-2323 (1977) Contraception, 16, pp. 155-165
dc.descriptionNash, H.A., Robertson, D.N., Moo Young, A.J. and Atkinson, L.E. Steroid release from SilasticR capsules and rods. (In preparation)
dc.languageen
dc.publisher
dc.relationContraception
dc.rightsfechado
dc.sourceScopus
dc.titleComparative Clinical Trial Of The Progestins R-2323 And Levonorgestrel Administered By Subdermal Implants
dc.typeArtículos de revistas


Este ítem pertenece a la siguiente institución